About half of cancer drugs given accelerated approval don't show improved survival or quality of life ( www.statnews.com )
For decades, the Food and Drug Administration’s accelerated approval pathway has helped companies get drugs for serious unmet medical needs to patients — and the market — sooner. But about half of cancer drugs approved via this route fail to improve patient survival or quality of life in subsequent clinical trials after...
